IMMUNOCIN ALPHA is a peptide immunomodulator containing thymosin alpha-1, a synthetic analogue of a naturally occurring thymic hormone. It is designed to enhance and regulate cellular immune response.
Mechanism of action:
Thymosin alpha-1 promotes T-lymphocyte maturation and differentiation, enhances natural killer cell activity, and increases interferon production. These effects strengthen antiviral defense while maintaining balanced immune regulation.
Recommended for:
Clinical evidence:
Thymosin alpha-1 has been evaluated in international clinical trials in chronic hepatitis B and C, demonstrating improved virological response rates when used in combination therapy. Studies also indicate reduced infectious complications in immunocompromised patients. Published data support its immunomodulatory efficacy and favorable safety profile under medical supervision.
Indicated for immune support in viral infections, immunodeficiency conditions, and as part of combination therapy in chronic inflammatory diseases. Enhances cellular immune response and improves resistance to infections.
Administered subcutaneously or intramuscularly as prescribed by a healthcare professional. Treatment regimen and duration depend on the clinical condition and individual immune status.
Contraindications
Side Effects
